Amlodipine/benazepril

Amlodipine/benazepril
Combination of
Amlodipine Calcium channel blocker
Benazepril ACE inhibitor
Clinical data
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration		 Oral
ATC code None
Legal status
Legal status
Identifiers
CAS Number 357437-90-2 N
PubChem (CID) 5746247
ChemSpider 4676979 YesY
 NYesY (what is this?)  (verify)

Amlodipine/benazepril, marketed in the U.S. as Lotrel by Novartis and manufactured as a generic drug by Teva and Sandoz, is an antihypertensive medication which combines a calcium channel blocker (amlodipine besilate) with an angiotensin converting enzyme inhibitor (benazepril).[1] This drug, like similar combinations, is prescribed when either agent alone is not sufficient to bring a person's blood pressure down to target range. As a combination agent, Lotrel shares the adverse reaction profile of both of its individual parts.[2][3]

See also

References

  1. ↑ Faulkner, Michele A; Hilleman, Daniel E (2005). "Amlodipine/benazepril: fixed dose combination therapy for hypertension". Expert Opinion on Pharmacotherapy. 2 (1): 165–178. doi:10.1517/14656566.2.1.165. ISSN 1465-6566.
  2. ↑ Drugs.com: Lotrel
  3. ↑ RxList.com: Lotrel

External links


This article is issued from Wikipedia - version of the 11/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.